Literature DB >> 23754881

Obstructive jaundice at the initial presentation in small-cell lung cancer.

Nobuaki Ochi1, Nagio Takigawa, Masayuki Yasugi, Etsuji Ishida, Hirofumi Kawamoto, Akihiko Taniguchi, Daijiro Harada, Eiko Hayashi, Hiroko Toda, Hiroyuki Yanai, Mitsune Tanimoto, Katsuyuki Kiura.   

Abstract

Obstructive jaundice sometimes may develop in association with advanced small-cell lung cancer (SCLC); however, SCLC initially presenting with obstructive jaundice is rare. This report presents the cases of two SCLC patients with obstructive jaundice at the initial diagnosis. A 64-year-old male presented with obstructive jaundice due to a tumor at the head of the pancreas. He was diagnosed with SCLC by transbronchial biopsy from a lung tumor in the left upper lobe. Another 74-year-old male was admitted with jaundice due to a tumor in the porta hepatis. He was also diagnosed with SCLC by a fine-needle aspiration biopsy of a lung tumor in the left lower lobe. Both cases were successfully treated with systemic chemotherapy after endoscopic retrograde biliary drainage.

Entities:  

Keywords:  biliary obstruction; jaundice; metastasis; small-cell lung carcinoma

Year:  2010        PMID: 23754881      PMCID: PMC3658212          DOI: 10.2147/imcrj.s8093

Source DB:  PubMed          Journal:  Int Med Case Rep J        ISSN: 1179-142X


Introduction

Lung cancer is the leading cause of cancer-specific mortality worldwide. Small-cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer and frequently develops distant metastases.1 SCLC potentially causes biliary duct obstruction by metastasizing to lymph nodes in the porta hepatis or the head of the pancreas. The primary sites of secondary tumors in the porta hepatis including the biliary tract, the head of the pancreas, and the ampulla of Vater associated with obstructive jaundice are gastric, colon, and breast cancer in that order. Only 1% of those tumors originate from lung cancer.2 Metastases to the pancreas were found in 26 (3.1%) of 850 lung cancer patients.3 Among 649 autopsy cases, 22 cases of metastases to the pancreas from a primary lung cancer were identified.4 Most of them did not present with clinical symptoms due to metastasis of the pancreas. Jaundice usually occurred as a late manifestation of widespread disseminated metastasis. This report presents the cases of two patients presenting with obstructive jaundice without any respiratory symptoms as the initial diagnosis of SCLC.

Case 1

A 64-year-old male who had smoked 90-pack-years presented with obstructive jaundice. He had jaundice and slight abdominal tenderness. The laboratory data were as follows: total bilirubin (T. Bil), 6.62 mg/dL; direct bilirubin (D. Bil), 4.3 mg/dL; aspartate aminotransferase (AST), 85 IU/L; alanine aminotransferase (ALT), 109 IU/L; γ-glutamyl transpeptidase (γ-GTP), 813 IU/L; neuron-specific enolase (NSE), 54.5 ng/mL; and pro-gastrin releasing peptide (pro-GRP), 1360 pg/mL. Abdominal ultrasonography (US) and computed tomography (CT) demonstrated an extrahepatic bile duct obstruction by a tumor at the head of the pancreas (measuring 47 mm in diameter) and intraabdominal lymph nodes. Chest CT showed a lung tumor in the left upper lobe invading the chest wall and mediastinal lymph nodes swelling (Figure 1). A specimen of a transbronchial biopsy showed SCLC. Finally, he had a diagnosis of extensive stage SCLC (T3N1M1). Endoscopic retrograde biliary drainage (ERBD) relieved the jaundice. He thereafter received combination chemotherapy with cisplatin and topotecan after the level of T. Bil decreased to a normal range. He achieved a partial response with mild toxicity and had survived for 25 months without obstructive jaundice. At autopsy, the ERBD was still effective despite the progression of intraabdominal disease and the pathological specimen of a primary lesion of SCLC (Figures 2a, 2b) showed the same histology as that of the lymph node around the drainage tube (Figures 2c, 2d).
Figure 1

Tumors in the left upper lobe of the lung (left) and in the porta hepatic (right).

Figure 2

Histology of the primary lung lesion (a: ×20, b: ×400) and metastatic lymph node around the drainage tube (c: ×20, d: ×400).

Case 2

A 74-year-old male with a 27-pack/year smoking history presented with anorexia and jaundice. He had moderate epigastric tenderness. The laboratory findings showed: T. Bil, 9.68 mg/dL; D. Bil, 6.37 mg/dL; AST, 479 IU/L; ALT, 587 IU/L; ALP, 1578 IU/L; γ-GTP, 917 IU/L; NSE, 125 ng/mL; and Pro-GRP, 1790 pg/mL. Abdominal US revealed intrahepatic bile duct dilatation and a tumor of 27 × 17 mm located in the parapancreatic head. CT imaging showed swelling of multiple abdominal lymph nodes and a left adrenal gland mass, and a lung tumor measuring 78 × 51 mm located in the left lower lobe (Figure 3). Swelling of the contralateral and ipsilateral mediastinal lymph nodes was also detected. A specimen of a fine-needle aspiration biopsy from the lung tumor confirmed the diagnosis of SCLC. Multiple brain metastases were detected by magnetic resonance imaging. He had a diagnosis of extensive stage SCLC (T4N3M1). He had hyponatremia (111 mEq/l) due to inappropriate antidiuretic hormone secretion by SCLC. He underwent combination chemotherapy with carboplatin and etoposide after ERBD relieved the jaundice and the T. Bil level was reduced to 1.42 mg/dL. He achieved a partial response; however, the SCLC progressed rapidly and he died after four months.
Figure 3

Tumors in the left lower lobe of the lung (left) and in the parapancreatic head (right)

Discussion

This report described two SCLC patients with obstructive jaundice at the initial presentation that were treated with systemic chemotherapy after ERBD. Only 11 cases of SCLC initially presenting obstructive jaundice have been reported.5–11 According to the oldest known report described by Dunkerley and colleagues in 1976, local radiation therapy was administered.5 In 1985, Johnson and colleagues described five patients that initially received systemic chemotherapy.6 Martin and colleagues also described one case that unfortunately died due to a sudden cardiac arrest before any treatment could be performed.7 One of the four more recent patients underwent surgery followed by chemotherapy,8 one underwent surgery alone,9 and two patients were treated with percutaneous transhepatic biliary drainage (PTBD) followed by chemotherapy.10,11 The patients in the current study were treated with ERBD before chemotherapy. ERBD is widely used for drainage of distal bile duct obstructions and PTBD is employed in difficult cases of ERBD.12 Obstructive jaundice by metastasis of SCLC should be noted even at the initial diagnosis because SCLC is highly sensitive to chemotherapy.
  12 in total

1.  Extrahepatic biliary obstruction caused by small-cell lung cancer: a case report.

Authors:  C Kotan; M Er; B Ozbay; K Uzun; I Barut; E Ozgoren
Journal:  Acta Chir Belg       Date:  2001 Jul-Aug       Impact factor: 1.090

2.  Extrahepatic biliary obstruction caused by small-cell lung cancer.

Authors:  D H Johnson; J D Hainsworth; F A Greco
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

3.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

Authors:  Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

4.  Metastatic cancer involving pancreatic duct epithelium and its mimicry of primary pancreatic cancer.

Authors:  S Matsukuma; K Suda; H Abe; S Ogata; R Wada
Journal:  Histopathology       Date:  1997-03       Impact factor: 5.087

5.  Patterns of pancreatic metastasis from lung cancer.

Authors:  T Maeno; H Satoh; H Ishikawa; Y T Yamashita; T Naito; M Fujiwara; H Kamma; M Ohtsuka; S Hasegawa
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

6.  A case of a small cell lung carcinoma presenting with jaundice due to pancreatic metastasis.

Authors:  Ayşin Sakar; Eray Kara; Hasan Aydede; Semin Ayhan; Pinar Celik; Arzu Yorgancioğlu
Journal:  Tuberk Toraks       Date:  2005

7.  Metastatic small cell lung cancer causing biliary obstruction.

Authors:  M Obara; H Satoh; Y T Yamashita; H Kamma; M Ohtsuka; S Hasegawa; K Orii
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

Review 8.  Percutaneous drainage and stenting for palliation of malignant bile duct obstruction.

Authors:  Otto M van Delden; Johan S Laméris
Journal:  Eur Radiol       Date:  2007-10-25       Impact factor: 5.315

Review 9.  Biliary tract obstruction secondary to cancer: management guidelines and selected literature review.

Authors:  J J Lokich; R A Kane; D A Harrison; W V McDermott
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

Review 10.  Cholestatic jaundice as the presenting symptom of small cell lung cancer.

Authors:  A Martin; I Castagliuolo; G Mastropaolo; G Del Favero; F Di Mario; F Farinati; G Sturniolo; A Cecchetto; R Naccarato
Journal:  Ital J Gastroenterol       Date:  1990-02
View more
  5 in total

Review 1.  Lung carcinoma presenting as an obstructive jaundice: case series with literature review.

Authors:  Dhara Chaudhari; Atul Khanna; Puneet Goenka; Mark Young
Journal:  J Gastrointest Cancer       Date:  2014-12

2.  A presenting with obstructive jaundice in pulmonary adenocarcinoma: a case report.

Authors:  Chang-Zhong Yu; Cong-Hui Yu; Chao Nai; Ju Tian
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 3.  Pancreatic involvement in small cell lung cancer.

Authors:  Ugur Gonlugur; Arzu Mirici; Muammer Karaayvaz
Journal:  Radiol Oncol       Date:  2014-01-22       Impact factor: 2.991

4.  Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma.

Authors:  Nobuaki Ochi; Daisuke Goto; Hiromichi Yamane; Tomoko Yamagishi; Yoshihiro Honda; Yasumasa Monobe; Hirofumi Kawamoto; Nagio Takigawa
Journal:  Onco Targets Ther       Date:  2014-10-07       Impact factor: 4.147

Review 5.  Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer.

Authors:  Takeshi Okamoto
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.